Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 2023 Dec 15:S0140-6736(23)02408-X. doi: 10.1016/S0140-6736(23)02408.
PMID: 38109916